New York: Swiss pharmaceuticals giant Roche announced plans to invest $50 billion in the US in pharmaceuticals and diagnostics amid concerns about potential new US tariffs on pharmaceutical imports.

According to Anadolu Agency, the investment is expected to generate more than 12,000 new jobs, with 1,000 positions at Roche and more than 11,000 supporting new US manufacturing capabilities. Roche emphasized its significant US presence, which includes over 25,000 employees, 15 research and development centers, and 13 manufacturing sites.

The company plans to develop new, advanced R and D facilities and enhance its production plants in California, Massachusetts, Indiana, and Pennsylvania. A new R and D facility in Massachusetts will focus on treatments for metabolism, kidney disease, and cardiovascular disease, as well as AI research. Furthermore, a new 900,000-square-foot manufacturing facility will be built at an undisclosed location to support Roche's expanding portfolio of next-generation weight loss medicines.

Roche indicated that upon completion of the additional manufacturing capacity investments, it will export more medications from the US than it imports. Thomas Schinecker, Roche Group CEO, expressed pride in the company's 110-year legacy in the United States, highlighting its role in driving jobs, innovation, and intellectual property creation. Schinecker stated that the $50 billion investment over the next five years will set the stage for the next era of innovation and growth, benefiting patients in the US and worldwide.

The investment announcement follows US President Donald Trump's threats to remove the pharmaceutical industry's exemption from his tariffs. Trump indicated that a significant tariff on pharmaceuticals would be announced soon.